
price data provid thomson reuter
number may add due round
remain de-risk platform name near-term cash need
support valuat op laura chico ultomiri royalti
potenti signific royalti stream tafasitamab licens
morphosi mor cover multipl early-stag pipelin candid
provid futur upsid resum treat patient ph studi
r/r acut myeloid leukemia aml patient
amend protocol follow fda lift partial clinic hold studi
among xncr bispecif antibodi compani provid updat
ph dose escal studi patient b-
cell malign expect data ph dose-escal
studi patient neuroendocrin tumor
gastrointenstin stromal tumor gist data
one xncr tumor microenviron tme activ bispecif antibodi
may xncr commenc phase studi two tme bispecif
antibodi ico see
futur updat program opportun upsid program
becom derisk build compani valu royalti
cash
note present annual wedbush pacgrow
healthcar confer new york tuesday august et regist
tafasitamab licens mor move closer bla file end
year ultomiri launch move global june confer
malign lymphoma icml lugano switzerland mor present primari
analysi data l-mind studi r/r dlbcl patient fit chemotherapi
autolog stem cell transplant least year follow-up
present result show patient treat tafasitamab combin
lenalidomid orr primari endpoint patient
complet respons median durat respons month
median progression-fre surviv month os rate
see fda recept tafasitamab given efficaci seen
take account limit treatment option r/r dlbcl patient
unfit therapi inde efficaci similar car-t treatment overal
efficaci durat respons better toler advers event profil
regard ultomiri expand global presenc recent approv
japan june europ juli paroxysm nocturn hemoglobinuria
june cash cash equival market
secur project adequ runway maintain oper beyond
second quarter year recogn revenu mainli
collabor astella continu page
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
develop number antibodi therapeut incorpor proprietari engin technolog
includ enter ph diseas number bispecif antibodi program
earlier stage develop also number partner asset includ fc-engin
antibodi partner morphosi ph dlbcl alexion-partn ultomiri recent
approv pnh overal believ market undervalu strength xncr pipelin platform
valid recent collabor roch therapeut astella
bispecif antibodi view number key competit advantag compet antibodi
approv
rd premium price
bispecif pipelin continu
advanc provid addit
clinic regulatori setback
inabl
achiev premium price high
initi ph data
mor bla submiss tafasitamab
submit ind genentech collab
initi ph data
sum-of-part multipl ww sale obexelimab
plu multipl
royalti ultomiri
steadi clinic progress pipelin candid
xncr
engin antibodi technolog potenti
applic varieti indic
clinical-stag biopharmaceut compani
focus discov develop engin
monoclon antibodi treat sever
threaten diseas unmet medic need
creat bluematrix
mileston royalti connect ultomiri research develop
cost quarter period last year gener
administr cost higher respect quarter
net loss period record per share ahead consensu
estim
reiter rate outperform increas pt sum-
of-part valuat deriv multipl us/ex-u sales/royalti
obexelimab discount back annual assum us co-promote/ex-u royalti
licens agreement multipl us/ex-u sales/royalti r/r
aml discount back annual multipl ww royalti
allerg asthma discount back annual multipl us/ex-u sale
discount back multipl ww
royalti mor-partn tafasitamab r/r dlbcl discount back plu
multipl ww street royalti alxn-partn ultomiri pnh discount back
annual chang pt reflect adjust updat consensu estim
ultomiri sale revis sale multipl
refin price metric tafasitamab valuat tabl model
mor-partn product expens oper incom interest incom non-op incom incom incom incom ep share dilut share thousand except per share data valuat
sum-of-part multipl ww sale obexelimab plu multipl royalti
ultomiri discount back
risk attain price rate
risk includ failur clinic failur achiev regulatori approv failur reach sale expect
lower expect royalti payment partner program
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
august
august
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
